MedTrace Logo

Baxdrostat and Ventricular Remodeling

NCT07655362 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 286

Last updated 2026-06-17

No results posted yet for this study

Summary

The goal of this trial is to learn whether adding the blood pressure medication baxdrostat (Baxfendy) to standard-of-care medical therapies will beneficially change the heart structure and function of adults who have high blood pressure, thickened left heart walls, and are at risk for heart or kidney disease.

To determine if baxdrostat improves heart structure and function, the participants will:

* take a baxdrostat or a placebo (a look-alike tablet that contains no drug) tablet once a day for 12 months
* undergo a safe and non-invasive cardiac magnetic resonance imaging scan (to measure heart mass, stiffness and function) at the beginning of the study and 12 months later
* visit the clinic for checkups and blood or urine tests 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months after taking the first tablet

Conditions

  • Cardiac Remodeling

Interventions

DRUG

Baxdrostat

Participants will take 2mg baxdrostat (Baxfendy) once daily (orally), in addition to standard-of-care.

DRUG

Placebo

Participants will take placebo once daily (orally), in addition to standard-of-care.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Subodh Verma

    lead OTHER

Principal Investigators

  • Subodh Verma, MD, PhD · North York Diagnostic and Cardiac Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2028-06-30
Completion
2028-12-31
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07655362 on ClinicalTrials.gov